Effects of intravenous enoxaparin and intravenous inogatran in an electrolytic injury model of venous thrombosis in the dog

Journal of Thrombosis and Thrombolysis

Volumn 6, Issue 3, 1998, Pages 199-206

  Ignasiak, Diane P ^a   McClanahan, Thomas B ^a   Bousley, Richard E ^a   Juneau, Paul L ^a   Gallagher, Kim P ^a  

^a PFIZER INC   (United States)

Author keywords

Electrolytic injury; Enoxaparin; Inogatran; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ELECTROLYTE; ENOXAPARIN; INOGATRAN; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; FEMALE; FEMORAL VEIN; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBUS; TIME; VEIN THROMBOSIS;

EID: 0032423061     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008806312396     Document Type: Article

References (33)

1. Haines ST, Bussey HI. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother 1995;29:892-905.
2. Anderson-FA J, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151:933-938.
3. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3 ed. Philadelphia: JB Lippincott, 1994:1275-1296.
4. Clagett GP, Anderson-FA J, Levine MN, Salzman EW, Wheeler HB. Prevention of venous thromboembolism [see comments]. Chest 1992;102:391S-407S.
5. FitzGerald GA. The human pharmacology of thrombin inhibition. Cor Art Dis 1996;7:911-918.
6. Weitz J. New anticoagulant strategies. Current status and future potential. Drugs 1994;48:485-497.
7. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association [published erratum appears in Circulation 1995 91:A55-A56]. Circulation 1994;89:1469-1480.
8. Tapparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low-molecular weight thrombin inhibitors: Molecular design and pharmacological profile Trends Pharmacol Sci 1993;14:366-376.
9. Hirsh J. Low molecular weight heparin. Thromb Haemost 1993;70:204-207.
10. Carter CA, Skoutakis VA, Spiro TE, et al. Enoxaparin: The low-molecular-weight heparin for prevention of postoperative thromboembolic complications [see comments]. Ann Pharmacother 1993;27:1223-1230.
11. Verstraete M. Direct thrombin inhibitors: Appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997;78:357-363.
12. Philippides GJ, Loscalzo J. Potential advantages of directacting thrombin inhibitors. Cor Art Dis 1996;7:497-507.
13. Teger-Nilsson AC, Bylund R, Gustafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Thromb Res 1997; 85:133-145.
14. Gustafsson D, Elg M. Lenfors S, Borjesson I, Teger NA. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul Fibrinolys 1996;7:69-79.
15. Buckley MM, Sorkin EM. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992;44: 465-497.
16. Cosmi B, Hirsh J. Low molecular weight heparins. Curr Opin Cardiol 1994;9:612-618.
17. Noble S, Peters DH, Goa KL. Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995; 49:388-410.
18. Haas S. The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. Haemostasis 1996;26(Suppl. 2): 39-48.
19. Eriksson BI, Wille JP, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement [see comments]. TV Engl J Med 1997;337: 1329-1335.
20. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393 [see comments]. Lancet 1996;347:635-639.
21. Uriuda Y, Wang QD, Grip L, Ryden L, Sjoquist PO, Mattsson C. Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closedchest porcine model of coronary artery thrombosis. Cardiovasc Res 1996;32:320-327.
22. Finkle CD, St. Pierre A, Leblond L, Deschenes I, DiMaio J, Winocour PD. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis - comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost 1998;79:431-438.
23. Preville P, He J, Tarazi M, Siddiqui M, Cody W, Doherty A. An efficient preparation of the potent and selective pseudopeptide thrombin inhibitor, inogatran. Bioorg Med Chem Lett 1997;7:1563-1566.
24. Carter CJ. New developments in acute anticoagulation therapy: What improvements over traditional heparin are on the horizon? Postgrad Med 1996;99:129-136.
25. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-1828.
26. Boneu B. Low molecular weight heparin therapy: Is monitoring needed? Thromb Haemost 1994;72:330-334.
27. Agnelli G, Iorio A, Renga C, et al. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995;92:2819-2824.
28. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-venin thrombosis. Lancet 1992;339:441-445.
29. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis [see comments]. Arch Intern Med 1995;155:601-607.
30. Goldhaber SZ. Practical aspects of venous thromboembolism prevention: An overview. Cardiovascular Reviews & Reports 1994;15(12):34-44.
31. Mousa SA, Mu DX, Lucchesi BR. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs. Stroke 1997;28:830-835.
32. Sudo Y, Lucchesi BR. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: A comparison with heparin. J Cardiovasc Pharmacol 1996; 27:545-555.
33. Rebello SS, Miller BV, Basler GC, Lucchesi BR. CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol 1997;29:240-249.